Abbott Laboratories $ABT Shares Sold by Cyndeo Wealth Partners LLC

Cyndeo Wealth Partners LLC cut its position in Abbott Laboratories (NYSE:ABT) by 8.8% during the 4th quarter, HoldingsChannel reports. The firm owned 160,061 shares of the healthcare product maker’s stock after selling 15,532 shares during the quarter. Abbott Laboratories makes up about 1.1% of Cyndeo Wealth Partners LLC’s investment portfolio, making the stock its 19th largest position. Cyndeo Wealth Partners LLC’s holdings in Abbott Laboratories were worth $20,054,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Carr Financial Group Corp raised its holdings in shares of Abbott Laboratories by 2.0% during the third quarter. Carr Financial Group Corp now owns 3,880 shares of the healthcare product maker’s stock valued at $520,000 after buying an additional 76 shares during the last quarter. Gemmer Asset Management LLC grew its holdings in Abbott Laboratories by 2.9% in the 3rd quarter. Gemmer Asset Management LLC now owns 2,750 shares of the healthcare product maker’s stock worth $368,000 after buying an additional 78 shares in the last quarter. Global Financial Private Client LLC increased its position in Abbott Laboratories by 3.3% in the 3rd quarter. Global Financial Private Client LLC now owns 2,469 shares of the healthcare product maker’s stock valued at $331,000 after acquiring an additional 79 shares during the period. Citizens & Northern Corp raised its stake in Abbott Laboratories by 0.4% during the 3rd quarter. Citizens & Northern Corp now owns 21,875 shares of the healthcare product maker’s stock valued at $2,930,000 after acquiring an additional 79 shares in the last quarter. Finally, Nia Impact Advisors LLC raised its stake in Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after acquiring an additional 79 shares in the last quarter. Institutional investors own 75.18% of the company’s stock.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott expects to close its acquisition of Exact Sciences on March 23, 2026, after receiving all regulatory clearances — a major strategic move that immediately expands Abbott’s presence in cancer screening and diagnostics and could drive revenue growth over time. Abbott acquisition of Exact Sciences set to close on March 23, 2026
• Positive Sentiment: Coverage and commentary highlight the strategic expansion into diagnostics with Exact Sciences, positioning Abbott to capture a larger share of growing cancer-screening markets — a long-term revenue and pipeline positive. Abbott (NYSE:ABT) Expands Diagnostics With Exact Sciences Amid S&P 500 Futures
• Positive Sentiment: Independent bullish write-ups (syndicated on Yahoo/InsiderMonkey) recap a bullish thesis on ABT, citing valuation metrics and growth potential tied to diagnostics exposure — such coverage can support investor interest and longer-term upside. Is Abbott Laboratories (ABT) A Good Stock To Buy Now?
• Neutral Sentiment: Macro/theme-level research (UBS longevity thematic piece) frames aging and longevity as structural tailwinds for companies exposed to diagnostics and chronic-care solutions; this supports ABT’s long-term thesis but is not an immediate catalyst. Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates
• Negative Sentiment: Healthcare stocks pulled back late Friday, dragging ABT with the sector; broader sector weakness can amplify short-term downside even when company-specific news is positive. Sector Update: Health Care Stocks Retreat Late Afternoon
• Negative Sentiment: Relative underperformance versus peers was noted in market reports — investors may be trimming ABT into the acquisition close due to integration, execution and dilution concerns. Abbott Laboratories stock underperforms Friday when compared to competitors

Abbott Laboratories Trading Down 1.5%

Shares of ABT stock opened at $105.58 on Friday. The stock has a 50-day simple moving average of $112.75 and a 200 day simple moving average of $123.03. The stock has a market capitalization of $183.88 billion, a P/E ratio of 28.38, a P/E/G ratio of 1.68 and a beta of 0.74. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.06. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion for the quarter, compared to analysts’ expectations of $11.80 billion. During the same period in the previous year, the business earned $1.34 earnings per share. Abbott Laboratories’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, sell-side analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 2.4%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. The Goldman Sachs Group decreased their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. BTIG Research reduced their price objective on shares of Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a report on Tuesday, February 17th. Piper Sandler lowered their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Freedom Capital upgraded shares of Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 29th. Finally, Weiss Ratings lowered shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, Abbott Laboratories presently has a consensus rating of “Moderate Buy” and a consensus target price of $136.16.

Insider Activity

In other news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the completion of the sale, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This represents a 2.32% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Elizabeth C. Cushman sold 263 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the transaction, the executive vice president owned 38,573 shares in the company, valued at $4,458,267.34. The trade was a 0.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock valued at $353,097 in the last ninety days. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.